Roche also announced first-quarter sales shrank 1%.
The drugmaker expects to return emerge from 2016 with over 5,000 fewer employees and return to growth mode in 2017.
Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.
Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.
The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.
Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.
The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.
Third-quarter earnings did not stir up analysts, who were more focused on the pipeline and Pfizer's future organizational plans.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
The CEO says Sanofi's patent-loss turnaround is coming.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.
The company narrowed its second quarter loss, but said its national TV campaign is driving an uptick in consumer interest.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
This is the second addition this year and brings the company's contracted sales force to 260.
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.
Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.